| Literature DB >> 33937548 |
Ryutaro Matsugaki1, Makoto Ohtani2, Yuko Mine1, Satoru Saeki3, Kiyohide Fushimi4, Shinya Matsuda1.
Abstract
OBJECTIVES: Pre-transplant rehabilitation for hematological malignancy patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) helps improve physical capacity. However, its benefit with respect to post-transplant hospital length of stay (LOS) is unclear. Consequently, the aim of this study was to investigate the effect of pre-transplant rehabilitation on post-transplant LOS for hematological malignancy patients undergoing allo-HSCT.Entities:
Keywords: allogeneic hematopoietic stem cell transplantation; hematological malignancy; length of stay; pre-transplant rehabilitation
Year: 2021 PMID: 33937548 PMCID: PMC8080154 DOI: 10.2490/prm.20210020
Source DB: PubMed Journal: Prog Rehabil Med ISSN: 2432-1354
Fig. 1.Patient selection flowchart. In total, 3614 patients with hematological malignancy undergoing allogeneic hematopoietic stem cell transplantation were included in the study.
Patient characteristics
| Total | Pre-transplant rehabilitation | ||||||
| Yes | No | ||||||
| n | (%) | n | (%) | n | (%) | P-value | |
| Number of patients | 3614 | 2728 | 886 | ||||
| Age (years), mean (SD) | 49.3 | (13.7) | 49.3 | (13.7) | 49.6 | (13.8) | 0.536 |
| Sex | 0.412 | ||||||
| Female | 1507 | (42) | 1148 | (42) | 359 | (41) | |
| Male | 2107 | (58) | 1580 | (58) | 527 | (59) | |
| Body mass index (kg/m2) | 0.934 | ||||||
| <18.5 | 585 | (16) | 445 | (16) | 140 | (16) | |
| 18.5 to <25.0 | 2490 | (69) | 1876 | (69) | 614 | (69) | |
| ≥25.0 | 539 | (15) | 407 | (15) | 132 | (15) | |
| Stem cell source | 0.038 | ||||||
| Bone marrow | 1532 | (42) | 1131 | (41) | 401 | (45) | |
| Peripheral blood | 1085 | (30) | 848 | (31) | 237 | (27) | |
| Cord blood | 997 | (28) | 749 | (27) | 248 | (28) | |
| Underlying disease | 0.105 | ||||||
| Myeloid leukemia | 1656 | (46) | 1252 | (46) | 404 | (46) | |
| Lymphoid leukemia | 973 | (27) | 715 | (26) | 258 | (29) | |
| Myelodysplastic syndrome | 560 | (16) | 442 | (16) | 118 | (13) | |
| Non-Hodgkin lymphoma | 363 | (10) | 278 | (10) | 85 | (10) | |
| Multiple myeloma | 36 | (1) | 23 | (1) | 13 | (2) | |
| Hodgkin lymphoma | 26 | (1) | 18 | (1) | 8 | (1) | |
| Charlson comorbidity index | 0.319 | ||||||
| 0 | 2835 | (78) | 2155 | (79) | 680 | (77) | |
| 1 | 477 | (13) | 354 | (13) | 123 | (14) | |
| ≥2 | 302 | (8) | 219 | (8) | 83 | (19) | |
| Secondary disease | |||||||
| Graft-versus-host disease | 490 | (11) | 277 | (10) | 113 | (13) | 0.030 |
| Cytomegalovirus infection | 193 | (5) | 145 | (5) | 48 | (5) | 0.906 |
| Bacterial infection | 12 | (0) | 9 | (0) | 3 | (0) | 0.969 |
| Candidiasis | 70 | (2) | 53 | (2) | 17 | (2) | 0.964 |
| Rehabilitation, mean (SD) | |||||||
| Interval between start of pre-transplant rehabilitation and HSCT (days) | 10.8 | (5.2) | |||||
| Interval between HSCT and start of post-transplant rehabilitation (days) | 11.8 | (20.9) | 5.2 | (10.1) | 31.8 | (30.3) | <0.001 |
| Duration of rehabilitation (days) | 35.9 | (24.5) | 38.3 | (24.2) | 28.2 | (23.9) | <0.001 |
| Frequency of rehabilitation (days/length of stay) | 0.39 | (0.2) | 0.43 | (0.2) | 0.26 | (0.1) | <0.001 |
| University hospital (yes) | 1750 | (49) | 1376 | (50) | 374 | (42) | <0.001 |
SD, standard deviation.
Comparison of outcomes between the pre-transplant rehabilitation and no-pre-transplant rehabilitation groups
| Pre-transplant rehabilitation | |||||||
| Yes | No | ||||||
| Mean | SD | 95% CI | Mean | SD | 95% CI | P- value | |
| Post-transplant length of stay (days) | 74.2 | 39.5 | 72.7–75.7 | 90.2 | 52.3 | 86.7–93.6 | <0.001 |
| Total length of stay (days) | 89.9 | 40.5 | 88.3–91.4 | 104.2 | 53.3 | 100.7–107.7 | <0.001 |
| Barthel index score at discharge | 93.8 | 22.3 | 92.9–94.6 | 93.1 | 22.2 | 91.6–94.6 | 0.430 |
| Total cost of hospitalization (USD) | 84,594 | 43,260 | 82,970–86,218 | 95,285 | 54,873 | 91,667–98,903 | <0.001 |
CI, confidence interval.
Multilevel linear regression analysis of factors influencing post-transplant length of hospital stay (log transformed)
| Univariate analysis | Multivariate analysis | |||||
| β | SE | P-value | β | SE | P-value | |
| Intercept | 4.251 | 0.042 | <0.001 | |||
| Age (years) | 0.001 | 0.001 | 0.023 | <0.001 | 0.001 | 0.378 |
| Male sex | –0.023 | 0.014 | 0.100 | –0.016 | 0.014 | 0.238 |
| Body mass index (kg/m2) | ||||||
| <18.5 | 0.026 | 0.019 | 0.171 | 0.007 | 0.019 | 0.701 |
| 18.5 to <25.0 | Reference | |||||
| ≥25.0 | –0.013 | 0.020 | 0.492 | –0.001 | 0.019 | 0.981 |
| Stem cell source | ||||||
| Bone marrow | Reference | |||||
| Peripheral blood | –0.081 | 0.017 | <0.001 | –0.072 | 0.017 | <0.001 |
| Cord blood | 0.115 | 0.017 | <0.001 | 0.144 | 0.017 | <0.001 |
| Underlying disease | ||||||
| Myeloid leukemia | Reference | |||||
| Lymphoid leukemia | 0.032 | 0.017 | 0.006 | 0.034 | 0.016 | 0.038 |
| Myelodysplastic syndrome | 0.024 | 0.020 | 0.238 | 0.025 | 0.020 | 0.217 |
| Non-Hodgkin lymphoma | 0.002 | 0.024 | 0.920 | 0.021 | 0.023 | 0.375 |
| Multiple myeloma | 0.132 | 0.070 | 0.059 | 0.124 | 0.068 | 0.066 |
| Hodgkin lymphoma | 0.227 | 0.082 | 0.015 | 0.247 | 0.079 | 0.002 |
| Charlson comorbidity index | ||||||
| 0 | Reference | |||||
| 1 | 0.005 | 0.021 | 0.825 | 0.006 | 0.021 | 0.787 |
| ≥2 | 0.099 | 0.026 | <0.001 | 0.078 | 0.026 | 0.002 |
| Secondary disease | ||||||
| Graft-versus-host disease | 0.110 | 0.024 | <0.001 | 0.091 | 0.024 | <0.001 |
| Cytomegalovirus infection | 0.162 | 0.032 | <0.001 | 0.127 | 0.032 | <0.001 |
| Bacterial infection | –0.135 | 0.119 | 0.259 | –0.162 | 0.116 | 0.161 |
| Candidiasis | –0.061 | 0.050 | 0.230 | –0.081 | 0.049 | 0.098 |
| Rehabilitation | ||||||
| Pre-transplant rehabilitation (yes) | –0.118 | 0.019 | <0.001 | –0.134 | 0.020 | <0.001 |
| Frequency of rehabilitation | 0.029 | 0.048 | 0.544 | 0.138 | 0.050 | 0.006 |
| University hospital (yes) | 0.027 | 0.037 | 0.462 | 0.049 | 0.037 | 0.175 |
SE, standard error.